Heterogeneity of epidermal growth factor receptor mutations within a mixed adenocarcinoma lung nodule

Nakano, Hirofumi; Soda, Hiroshi; Takasu, Mineyo; Tomonaga, Nanae; Yamaguchi, Hiroyuki; Nakatomi, Katsumi; Fujino, Satoru; Hayashi, Tomayoshi; Nakamura, Yoichi; Tsukamoto, Kazuhiro; Kohno, Shigeru

doi:10.1016/j.lungcan.2007.08.021

Cited by 41 publications

(25 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, studies on intratumoral and intertumoral heterogeneity have increased gradually (Kidd et al, 2008;Nakano et al, 2008;Wang et al, 2013). For clinical analysis, TKIs resistance in a proportion of patients with EGFR mutation is always explained by the heterogeneity of EGFR mutation between PT and metastatic lesions (Park et al, 2009), or even between parts of PT (Sakurada et al, 2008).…”

Section: Discussionmentioning

confidence: 99%

Comparison of Epidermal Growth Factor Receptor Mutations between Primary Tumors and Lymph Nodes in Non-small Cell Lung Cancer: a Review and Meta-analysis of Published Data

Wang

Fang²,

Hou³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) can predict the clinical response to tyrosine kinase inhibitor (TKI) therapy. However, EGFR mutations may be different in primary tumors (PT) and metastatic lymph nodes (MLN). The aim of this study was to compare EGFR mutations between PT and the corresponding MLN in NSCLC patients, and provide some guidelines for clinical treatment using TKI therapy. Materials and Methods: A systematic review and meta-analysis was performed with several research databases. Relative risk (RR) with the 95% confidence interval (CI) were used to investigate the EGFR mutation status between PT and the corresponding MLN. A random-effects model was used. Results: 9 publications involving 707 patients were included in the analysis. It was found that activation of EGFR mutations identified in PT and the corresponding MLN was 26.4% (187/707) and 19.9% (141/707), respectively. The overall discordance rate in our meta-analysis was 12.2% (86/707). The relative risk (RR) for EGFR mutation in PT relative to MLN was 1.33 (95%CI: 1.10-1.60; random-effects model). There was no significant heterogeneity between the studies (I 2 =5%, p=0.003). Conclusions: There exists a considerable degree of EGFR mutation discrepancy in NSCLC between PT and corresponding MLN, suggesting that tumor heterogeneity might arise at the molecular level during the process of metastasis.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of Epidermal Growth Factor Receptor Mutations between Primary Tumors and Lymph Nodes in Non-small Cell Lung Cancer: a Review and Meta-analysis of Published Data

Wang

Fang²,

Hou³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Additionally, several studies have reported finding intratumor heterogeneity of the EGFR mutation [17, [26][27][28].…”

Section: Discussion 250mentioning

confidence: 99%

Clinical and molecular analysis of synchronous double lung cancers

et al. 2012

Self Cite

View full text Add to dashboard Cite

“…Discordances in results between primary tumors and their metastatic foci varying between 11-50% (depending on the gene under investigation and the assay performed) have been observed. [12][13][14][15][16] Therefore, it is likely preferable to assay the metastasis, recurrence, or post-treatment sample. 17 …”

Section: Molecular Testingmentioning

confidence: 99%

Role of molecular studies in the diagnosis of lung adenocarcinoma

Yousem

2012

Modern Pathology

View full text Add to dashboard Cite

Molecular alterations in adenocarcinoma of the lung have resulted in new therapeutic options for treatment of high-stage disease. Such changes are usually mutually exclusive and can be documented in small specimen samples. Most analyses are DNA-based, utilizing sequencing or fluorescence in situ hybridization to observe amplifications or translocations. Particular success in theranostics has focused on epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase gene (ALK), and BRAF gene changes, each allowing personalized therapies. Interestingly, these molecular changes have correlated with distinct, although not unique, demographics, histopathologies, and response to pharmacological agents.

show abstract

Heterogeneity of epidermal growth factor receptor mutations within a mixed adenocarcinoma lung nodule

Cited by 41 publications

References 16 publications

Comparison of Epidermal Growth Factor Receptor Mutations between Primary Tumors and Lymph Nodes in Non-small Cell Lung Cancer: a Review and Meta-analysis of Published Data

Comparison of Epidermal Growth Factor Receptor Mutations between Primary Tumors and Lymph Nodes in Non-small Cell Lung Cancer: a Review and Meta-analysis of Published Data

Clinical and molecular analysis of synchronous double lung cancers

Role of molecular studies in the diagnosis of lung adenocarcinoma

Contact Info

Product

Resources

About